MENU × BUSINESS
Banking And InsuranceCryptocurrencyDigital MarketingErpFood And BeveragesHealthcareLegalMarketing And AdvertisingMedia And EntertainmentMetals And MiningOil And GasRetailTelecom
TECHNOLOGY
Artificial IntelligenceBig DataCloudCyber SecurityE CommerceEducationGaming And VfxIT ServiceMobileNetworkingSAPScience And TechnologySecuritySoftwareStorage
PLATFORM
CiscoDatabaseGoogleIBMJuniperM2MMicrosoftOracleOracleRed Hat
LEADERSHIP
CEO ReviewCompany Review
MAGAZINE
ASIA INDIA
STARTUPS CLIENT SPEAK CONTACT US

The Silicon Review Asia

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Aurobindo Pharma Seeks to Add A Couple of Branded Products Acrotech Biopharma’s Portfolio

Hyderabad based pharmaceutical manufacturing company, Aurobindo Pharma Limited, has been a bit slow on the acquisition front. It had made some key acquisitions in the past and is now considering to add a few branded products to its subsidiary, Acrotech Biopharma’s portfolio. After acquiring a portfolio of seven oncology injectable products from US-based Spectrum Pharmaceuticals Inc for $300 million, Acrotech Biopharma hopes to generate a revenue of around $100 million from it for the initial year after the completion of the transaction for Aurobindo.

At the Q3FY19 results conference call, N Govindarajan, Managing Director of Aurobindo Pharma, said that they keep evaluating their domestic business sometimes, but now they are prioritising to integrate what they have acquired. This could take time and therefore, they will just stick to adding a couple of branded products into the portfolio instead of making any large acquisition. He also said that Aurobindo Pharma will be overseeing the dietary supplements segment in India in the long-term as well as file approvals for at least two biosimilar products in 2020.“Subsequent year we should get approval as far as Europe is concerned as approval time is around 210-days if everything is in line in terms of the filing. As far as US is concerned, you should estimate around 12 to 18 months for approval from the date of filing”, he added.

Aurobindo Pharma hopes to commercialise its product in the Chinese market after two and a half years. Presently, it has received the permits for building its facility, set to be completed within a year.

YOU MAY ALSO LIKE

Marketing Partnership: NBA, McDonald’s Will Jointly open NBA Experience Zones India

There is good news for all basketball fans in India. Very soon, NBA themed promotions and experience zones will be launched in India. The announcement...

Dunzo to Raise Funds from Google, others

Dunzo, the app which is trying to make life easier for the people upto some extent plans to raise about Rs. 183 crore from different investors which a...

Sapta Shakti Command Will Be Displaying Defence Technology Equipment at Jaipur Military Station

This event is organised with an aim to provide an opportunity where one and all can experience the developments in the field of defence and security-r...

Samsung is All Set to Roll out Its Galaxy A9 Smartphone On November 20

After Samsung unveiled its new Galaxy A9 smartphone in Singapore last month, the company is all set to launch it in India on November 20. In Singapore...

RECOMMENDED